Last updated: September 9, 2026
Brimonidine tartrate and timolol maleate are established glaucoma medicines sold both as separate ophthalmic products and as the fixed-dose combination Combigan. The combination is an FDA-approved prescription eye drop for lowering elevated intraocular pressure in patients with ocular hypertension or glaucoma. Its commercial trajectory has shifted from branded growth to mature-market defense and generic erosion.
The main financial exposure is Combigan, marketed originally by Allergan and now within AbbVie’s ophthalmology portfolio. AbbVie does not separately disclose Combigan revenue in its public filings, so product-level sales cannot be calculated from reported financial statements. The commercial outlook is shaped by generic entry, payer substitution, preservative-free competition, and the continued use of brimonidine and timolol as low-cost components of glaucoma therapy.
What is brimonidine tartrate and timolol maleate?
Brimonidine tartrate is an alpha-2 adrenergic receptor agonist. Timolol maleate is a nonselective beta-adrenergic blocker. Both reduce aqueous humor production, while brimonidine also increases uveoscleral outflow.
The fixed-dose combination reduces intraocular pressure through two complementary pharmacologic mechanisms.
| Product or API |
Drug class |
Primary role |
Common dosage form |
| Brimonidine tartrate |
Alpha-2 adrenergic agonist |
Reduces aqueous humor production and increases uveoscleral outflow |
Ophthalmic solution |
| Timolol maleate |
Nonselective beta blocker |
Reduces aqueous humor production |
Ophthalmic solution or gel |
| Combigan |
Brimonidine tartrate 0.2% plus timolol maleate 0.5% |
Combination glaucoma therapy |
Multidose ophthalmic solution |
Combigan is generally administered as one drop in the affected eye twice daily. The product’s value proposition is reduced drop burden compared with administering brimonidine and timolol separately. The FDA approved Combigan in October 2007 for patients requiring adjunctive therapy for elevated intraocular pressure.[1]
What is the FDA regulatory status of brimonidine-timolol?
Combigan is an FDA-approved new drug application product. Its regulatory identity is defined by the combination of brimonidine tartrate 0.2% and timolol maleate 0.5% in an ophthalmic solution.
The separate active ingredients have long-standing generic status:
- Brimonidine tartrate ophthalmic solution is available in generic strengths, primarily 0.2%.
- Timolol maleate ophthalmic products are available in multiple generic formulations, including solutions and gel-forming products.
- The fixed-dose combination is approved through an NDA and has subsequently faced abbreviated new drug application competition.
The combination is a small-molecule drug, not a biologic. Biosimilar substitution is therefore not relevant. Competitive entry occurs through ANDAs rather than the biosimilar pathway.
The principal clinical and regulatory limitations are consistent with the individual ingredients. Brimonidine can cause ocular allergy, conjunctival hyperemia, fatigue, and dry mouth. Timolol can produce systemic beta-blocker effects, including bradycardia, hypotension, bronchospasm, and worsening of certain cardiac or pulmonary conditions.[1]
What patents protect Combigan and the brimonidine-timolol combination?
The original Combigan patent estate included composition and combination-use protection. A historically important patent is U.S. Patent No. 6,641,834, which covered ophthalmic compositions containing brimonidine and timolol. Later patents addressed combination formulations and methods of use.
| Patent |
Subject matter |
Commercial relevance |
| U.S. Patent No. 6,641,834 |
Brimonidine and timolol ophthalmic combination |
Core early combination protection |
| U.S. Patent No. 8,927,592 |
Later combination or formulation-related protection associated with brimonidine-timolol ophthalmic therapy |
Potential later-term barrier depending on claim scope and listing status |
| Orange Book-listed patents |
Product-specific claims submitted by the NDA holder |
Determine Paragraph IV exposure and regulatory delay |
Patent protection for the core commercial product has largely matured. The existence of a later patent does not automatically prevent generic approval. The practical effect depends on whether the patent is listed in the Orange Book, whether the ANDA applicant files a Paragraph IV certification, whether litigation is initiated, and whether the asserted claims survive litigation or settlement.
The FDA Orange Book remains the controlling public source for listed patents, expiration dates, and exclusivity information for approved drug products.[2]
When did Combigan lose exclusivity?
Combigan’s principal regulatory exclusivity period expired years before the current mature-market phase. The key commercial protection came from patents rather than long-duration statutory exclusivity.
| Event |
Timing |
| FDA approval of Combigan |
2007 |
| Initial branded commercialization |
Late 2000s |
| Core patent protection |
Expired or substantially weakened during the early 2020s |
| Generic competition |
Emerged after patent and regulatory barriers diminished |
| Current market phase |
Mature product with generic and branded competition |
The fixed-dose combination is no longer an early-life specialty product. Revenue is exposed to generic substitution, lower net pricing, formulary pressure, and reduced physician sensitivity to brand differentiation.
How many patents cover brimonidine tartrate and timolol maleate?
The answer depends on whether the scope includes the active ingredients, combination product, formulations, manufacturing processes, and method-of-use claims.
The active ingredients themselves are long off patent. Commercial protection has instead centered on:
- The fixed-dose combination.
- Concentration and dosing combinations.
- Ophthalmic vehicle and preservative systems.
- Methods for reducing intraocular pressure.
- Manufacturing and packaging configurations.
- Adjacent delivery technologies, including preservative-free systems.
A patent count based only on the Orange Book is usually lower than a worldwide patent-family count. Orange Book listings capture patents tied to an approved product in the United States, while global patent families can include abandoned applications, expired rights, pending continuations, and country-specific claims.
The practical patent estate is therefore narrower than the raw number of published patent documents. The strongest remaining barriers are formulation and delivery claims with enforceable terms, not the basic pharmacology of brimonidine or timolol.
What is the Orange Book status of Combigan?
The Orange Book identifies approved drug products, therapeutic equivalence information, patents, and regulatory exclusivity. For a generic applicant, the relevant question is whether listed patents remain enforceable and whether the applicant’s certification creates litigation exposure.
Generic applicants can use:
- Paragraph I certification when no patent information is listed.
- Paragraph II certification when listed patents have expired.
- Paragraph III certification when the applicant will wait until patent expiration.
- Paragraph IV certification when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.
A Paragraph IV filing can trigger a patent lawsuit within 45 days. A timely lawsuit can impose a 30-month stay on FDA approval, subject to statutory exceptions and court developments.[3]
For Combigan, the strategic significance of Orange Book patents has declined as core patent terms matured. Remaining listed patents may still affect timing, but the product no longer has the profile of a high-value, early-stage branded medicine protected by a broad patent wall.
Which companies are challenging Combigan?
Competition has come primarily from generic ophthalmic manufacturers rather than from biosimilar developers. Potential participants include companies with established sterile ophthalmic manufacturing capacity, such as:
- Akorn and its successor commercial assets.
- Bausch + Lomb.
- Sandoz.
- Teva Pharmaceuticals.
- Lupin.
- Apotex.
- Micro Labs.
- Other ANDA sponsors with ophthalmic manufacturing facilities.
The exact set of marketed suppliers changes as approvals are transferred, products are discontinued, and manufacturers face sterile manufacturing constraints. FDA approval of an ANDA does not guarantee broad commercial distribution. Ophthalmic products require specialized sterile filling, container-closure systems, stability data, and manufacturing compliance.
What patent litigation affects brimonidine-timolol products?
Patent litigation risk has historically centered on ANDA Paragraph IV challenges to combination-product patents. The key litigation questions are:
- Whether the generic product falls within the asserted claims.
- Whether the claims are invalid for obviousness or lack of written description.
- Whether formulation differences avoid infringement.
- Whether a patent was properly listed in the Orange Book.
- Whether settlement terms delay commercial launch.
The litigation profile is more limited than for blockbuster oral drugs because the market value of Combigan is lower and the product is clinically mature. Litigation economics favor negotiated settlements when expected legal costs approach the remaining branded profit pool.
Public filings from AbbVie describe broad intellectual-property and litigation risks but do not separately quantify Combigan litigation exposure or product-level settlement economics.[4]
Are there settlement agreements involving generic Combigan?
Generic settlements can establish a launch date before the final expiration of all listed patents. They can also include licenses, non-assert provisions, or agreements tied to regulatory approval.
The commercial effect of a settlement depends on:
- The agreed launch date.
- The number of generic entrants at launch.
- Whether the generic is authorized or independently marketed.
- Whether the product receives 180-day first-filer exclusivity.
- Whether the market has already shifted to alternative glaucoma therapies.
A settlement that permits one generic entrant can preserve some branded economics. Several simultaneous entrants usually produce faster price erosion.
What formulations are protected by brimonidine-timolol patents?
Formulation protection is commercially more important than API protection. Relevant formulation variables include:
- Brimonidine and timolol concentrations.
- pH and buffering systems.
- Osmolarity.
- Preservative concentration.
- Viscosity and drop size.
- Container-closure compatibility.
- Chemical stability of both active ingredients.
- Preservative-free delivery.
- Multidose versus unit-dose packaging.
Combigan’s branded formulation uses benzalkonium chloride as a preservative, which creates a competitive opening for preservative-free or better-tolerated products. Chronic glaucoma patients may experience ocular-surface disease, and physicians can switch patients to alternative formulations when tolerability is a concern.
A generic that matches the reference product closely can gain therapeutic-equivalence status. A materially different delivery system may require additional regulatory work and may compete on tolerability rather than price alone.
What is the financial trajectory for Combigan?
Combigan’s financial trajectory follows the standard pattern for a mature branded ophthalmic product:
| Phase |
Financial characteristics |
| Launch and adoption |
Combination convenience supported physician uptake |
| Growth phase |
Revenue benefited from brand recognition and combination prescribing |
| Patent-protected phase |
Pricing remained supported by limited direct combination competition |
| Generic-entry phase |
Volume shifted to lower-priced products; branded share declined |
| Mature phase |
Revenue depends on residual brand loyalty, supply reliability, and formulation differentiation |
AbbVie reports ophthalmology revenue at a portfolio level and does not provide a standalone annual revenue line for Combigan. The company’s public reporting therefore cannot support a precise product-level revenue or margin estimate.[4]
The principal revenue drivers are:
- Prescription volume in glaucoma and ocular-hypertension patients.
- Generic penetration.
- Net price after rebates and payer discounts.
- Share of patients requiring combination therapy.
- Availability of lower-cost individual components.
- Physician preference for fixed-dose dosing.
- Product shortages among generic manufacturers.
The principal downside risks are generic substitution and therapeutic substitution. Physicians can prescribe separate generic brimonidine and timolol, a generic fixed-dose combination, prostaglandin analogs, carbonic anhydrase inhibitors, rho-kinase inhibitors, or surgical and laser interventions.
How does Combigan compare with separate brimonidine and timolol?
| Factor |
Combigan |
Separate brimonidine plus timolol |
| Administration |
One product, typically twice daily |
Two bottles and potentially different schedules |
| Adherence |
Simpler regimen |
Higher drop burden |
| Cost |
Historically higher branded cost; generic pricing narrows difference |
Usually low-cost generic therapy |
| Preservative exposure |
Single combination formulation |
Exposure from two products |
| Dose flexibility |
Limited to fixed concentrations |
Individual dose and timing adjustment |
| Commercial differentiation |
Convenience and adherence |
Price and prescribing flexibility |
The combination can retain clinical value even after patent expiry because it reduces administration burden. Its commercial premium is harder to sustain once a therapeutically equivalent generic is available.
What generic entry risks exist?
Generic entry risk is high because:
- The active ingredients are well understood.
- The product is a conventional ophthalmic solution.
- Clinical use is established.
- The reference product has a long safety record.
- Generic manufacturers can rely on bioequivalence and pharmaceutical-equivalence pathways rather than new clinical development.
Manufacturing remains a meaningful operational barrier. Sterile ophthalmic products require validated aseptic processes, quality-control testing, container-closure integrity, and reliable supply of active ingredients and packaging. These barriers can delay launches or create shortages, but they rarely preserve long-term branded pricing once several suppliers qualify.
The most likely launch scenarios are:
- One early generic enters and captures price-sensitive prescriptions.
- Multiple generics enter, producing rapid price compression.
- Brand retains a niche based on availability, physician familiarity, or contracting.
- Preservative-free and alternative glaucoma products take share from both branded and generic Combigan.
What licensing deals affect brimonidine and timolol?
The commercial history is primarily associated with Allergan, which developed and marketed Combigan before AbbVie acquired Allergan in 2020. The acquisition transferred Combigan into AbbVie’s ophthalmology portfolio.[5]
No major, separately disclosed licensing transaction is central to the current commercial valuation of the product. The relevant strategic transaction is the Allergan acquisition, not a product-specific licensing agreement. Regional distribution and commercialization arrangements may exist, but they do not change the core U.S. generic-entry dynamics.
What is the competitive landscape for glaucoma products?
Combigan competes across several categories:
- Prostaglandin analogs, including latanoprost, bimatoprost, and travoprost.
- Alpha-2 agonists, including brimonidine.
- Beta blockers, including timolol.
- Carbonic anhydrase inhibitors, including dorzolamide and brinzolamide.
- Fixed combinations involving prostaglandins, carbonic anhydrase inhibitors, and beta blockers.
- Rho-kinase inhibitors.
- Laser and surgical interventions.
Prostaglandin analogs often remain first-line therapy because of strong intraocular-pressure reduction and once-daily dosing. Combigan is more relevant for patients who need additional pressure control or who cannot use a prostaglandin effectively.
What geographic coverage does the product have?
Brimonidine and timolol are marketed in multiple jurisdictions, but product names, concentrations, indications, and patent positions vary by country. U.S. commercial economics are governed by FDA approval, Orange Book listings, payer substitution, and ANDA competition.
In Europe and other markets, national reimbursement systems and tender purchasing can accelerate price erosion. Local patent terms, supplementary protection certificates, regulatory exclusivity, and country-specific generic approvals determine launch timing. The global opportunity is therefore fragmented rather than controlled by a single worldwide exclusivity date.
How strong is the patent estate for brimonidine-timolol?
The patent estate is weak for the active ingredients and moderate to limited for the branded fixed-dose combination. Core composition protection has matured. Residual strength depends on specific formulation claims, Orange Book listing status, patent expiration, and the ability to prove infringement.
The estate does not provide durable protection against all glaucoma competition. It may delay a directly substitutable generic, but it cannot prevent substitution by separate generic ingredients or competing therapeutic classes.
Key Takeaways
- Brimonidine tartrate and timolol maleate are mature generic APIs.
- Combigan is the principal branded fixed-dose combination of the two agents.
- FDA approval occurred in 2007.
- Core combination patent protection has largely matured, shifting the product into generic-entry economics.
- No biosimilar pathway applies because the product is a small molecule.
- Generic risk is high, although sterile ophthalmic manufacturing can affect launch timing.
- AbbVie does not separately disclose Combigan revenue.
- Future value depends on residual brand share, supply reliability, adherence benefits, and formulation differentiation.
- Preservative-free products and competing glaucoma classes create ongoing substitution pressure.
- The strongest remaining commercial arguments are convenience and tolerability, not basic patent exclusivity.
FAQs
Is Combigan still under patent protection?
Core patent protection has substantially matured. Any remaining impact depends on current Orange Book listings, patent terms, claim scope, and generic litigation or settlement outcomes.
Can patients use generic brimonidine and timolol instead of Combigan?
Yes. Physicians may prescribe the two generic products separately or use an approved generic fixed-dose combination when clinically appropriate.
Does Combigan have a biosimilar competitor?
No. Combigan is a small-molecule ophthalmic drug, so competitors use generic drug approval pathways rather than biosimilar regulation.
Why might a physician prescribe Combigan after generic entry?
The fixed-dose product reduces bottle count and dosing complexity. Some physicians may also prefer its known formulation, availability, or patient familiarity.
What is the largest financial risk to the Combigan franchise?
The largest risk is sustained generic substitution combined with therapeutic switching to other glaucoma drug classes, which reduces both branded volume and pricing power.
References
-
U.S. Food and Drug Administration. (2007). Combigan (brimonidine tartrate and timolol maleate) ophthalmic solution prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and patent certifications. FDA.
-
AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. AbbVie.
-
AbbVie Inc. (2020). AbbVie completes acquisition of Allergan. AbbVie.
